Existing users Log In New users Sign up


New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond

DISCOVERIES (ISSN 2359-7232), 2014, April-June

CITATION: 
Megan Keniry, Robert K. Dearth, Michael Persans, and Ramon Parsons. New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond. Discoveries 2014, Apr-Jun; 2(2): e15. DOI: 10.15190/d.2014.7

Submitted: April 28, 2014; Revised: June 29, 2014; Accepted: June 30, 2014; Published: June 30, 2014;

GO BACK to 2014, April-June issue 
GO BACK to DISCOVERIES

New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond


(1,*),  (1) (1) (2,*)


(1) Department of Biology, University of Texas - Pan American, 1201 W. University Dr., Edinburg, TX 78539, USA.

(2) Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave HCSM 6-117, New York, NY 10029, USA

*Correspondence to:

*Ramon Parsons, MD, PhD, Dept. of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave HCSM 6-117, New York, NY 10029, USA; Phone: 212-824-9331; ramon.parsons@mssm.edu 

*Megan Keniry, PhD, Dept. of Biology, University of Texas - Pan American, 1201 W. University Dr. Edinburg, TX 78539, USA; Phone: (965)-665-7463; Fax: (956) 665-3657; keniryme@utpa.edu

Abstract

The bZIP transcription factor NFIL3 (Nuclear factor Interleukin 3 regulated, also known as E4 binding protein 4, E4BP4) regulates diverse biological processes from circadian rhythm to cellular viability.  Recently, a host of novel roles have been identified for NFIL3 in immunological signal transduction, cancer, aging and metabolism. Elucidating the signaling pathways that are impacted by NFIL3 and the regulatory mechanisms that it targets, inhibits or activates will be critical for developing a clearer picture of its physiological roles in disease and normal processes.  This review will discuss the recent advances and emerging issues regarding NFIL3-mediated transcriptional regulation of CEBPb and FOXO1 activated genes and signal transduction.

Access full text of the manuscript here: 

References

1.   Seillet C, Jackson JT, Markey KA, Brady HJ, Hill GR, Macdonald KP, et al. CD8alpha+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood. 2013;121(9):1574-83. Epub 2013/01/09.

2.   Keniry M, Pires MM, Mense S, Lefebvre C, Gan B, Justiano K, et al. Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes & Development. 2013;27(8):916-27. Epub 2013/05/01.

3.   Carey KT, Tan KH, Ng J, Liddicoat DR, Godfrey DI, Cole TJ. Nfil3 is a glucocorticoid-regulated gene required for glucocorticoid-induced apoptosis in male murine T cells. Endocrinology. 2013;154(4): 1540-52. Epub 2013/02/22.

4.  Progatzky F, Taylor H, Bugeon L, Cassidy S, Radbruch A, Dallman MJ, et al. The role of Nfil3 in zebrafish hematopoiesis. Developmental and Comparative Immunology. 2012;38(1):187-92. Epub 2012/05/09.

5.  Monnier V, Iche-Torres M, Rera M, Contremoulins V, Guichard C, Lalevee N, et al. dJun and Vri/dNFIL3 are major regulators of cardiac aging in Drosophila. PLoS Genetics. 2012;8(11):e1003081. Epub 2012/12/05.

6.   Smith AM, Qualls JE, O'Brien K, Balouzian L, Johnson PF, Schultz-Cherry S, et al. A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. The Journal of Biological Chemistry. 2011;286(26): 23582-90. Epub 2011/05/14.

7.  MacGillavry HD, Cornelis J, van der Kallen LR, Sassen MM, Verhaagen J, Smit AB, et al. Genome-wide gene expression and promoter binding analysis identifies NFIL3 as a repressor of C/EBP target genes in neuronal outgrowth. Molecular and Cellular Neurosciences. 2011;46(2):460-8. Epub 2010/11/30.

8.   Li F, Liu J, Jo M, Curry TE, Jr. A role for nuclear factor interleukin-3 (NFIL3), a critical transcriptional repressor, in down-regulation of periovulatory gene expression. Molecular Endocrinology. 2011;25(3): 445-59.

9.  Kobayashi T, Matsuoka K, Sheikh SZ, Elloumi HZ, Kamada N, Hisamatsu T, et al. NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity. Journal of Immunology. 2011;186(8): 4649-55. Epub 2011/03/09.

10. Kashiwada M, Pham NL, Pewe LL, Harty JT, Rothman PB. NFIL3/E4BP4 is a key transcription factor for CD8alpha(+) dendritic cell development. Blood. 2011;117(23):6193-7. Epub 2011/04/09.

11. Rothman PB. The transcriptional regulator NFIL3 controls IgE production. Transactions of the American Clinical and Climatological Association. 2010;121: 156-71; discussion 71. Epub 2010/08/11.

12. Kashiwada M, Levy DM, McKeag L, Murray K, Schroder AJ, Canfield SM, et al. IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci U S A. 2010; 107(2): 821-6. Epub 2010/01/19.

13. MacGillavry HD, Stam FJ, Sassen MM, Kegel L, Hendriks WT, Verhaagen J, et al. NFIL3 and cAMP response element-binding protein form a transcriptional feedforward loop that controls neuronal regeneration-associated gene expression. The Journal of Neuroscience. 2009;29(49):15542-50. Epub 2009/12/17.

14. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld G, et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. The Journal of Experimental Medicine. 2009;206(13):2977-86. Epub 2009/12/10.

15. Ozkurt IC, Tetradis S. Parathyroid hormone-induced E4BP4/NFIL3 down-regulates transcription in osteoblasts. The Journal of Biological Cchemistry. 2003;278(29):26803-9. Epub 2003/05/14.

16. Cowell IG. E4BP4/NFIL3, a PAR-related bZIP factor with many roles. BioEssays: news and reviews in molecular, cellular and developmental biology. 2002;24(11):1023-9. Epub 2002/10/19.

17. Hulme DJ, Blair IP, Dawkins JL, Nicholson GA. Exclusion of NFIL3 as the gene causing hereditary sensory neuropathy type I by mutation analysis. Human Genetics. 2000; 106(6):594-6. Epub 2000/08/15.

18. Kuribara R, Kinoshita T, Miyajima A, Shinjyo T, Yoshihara T, Inukai T, et al. Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes. Molecular and Cellular Biology. 1999;19(4):2754-62. Epub 1999/03/19.

19. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A. 1997;94(6):2609-14. Epub 1997/03/18.

20. Mitsui S, Yamaguchi S, Matsuo T, Ishida Y, Okamura H. Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. Genes & Development. 2001;15(8):995-1006. Epub 2001/04/24.

21. Ozkurt IC, Pirih FQ, Tetradis S. Parathyroid hormone induces E4bp4 messenger ribonucleic acid expression primarily through cyclic adenosine 3',5'-monophosphate signaling in osteoblasts. Endocrinology. 2004; 145(8): 3696-703.

22. Lai CK, Ting LP. Transcriptional repression of human hepatitis B virus genes by a bZIP family member, E4BP4. Journal of Virology. 1999;73(4): 3197-209. Epub 1999/03/12.

23. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, Seddon B, et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol. 2009;10(10):1118-24. Epub 2009/09/15.

24. Tong X, Muchnik M, Chen Z, Patel M, Wu N, Joshi S, et al. Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. The Journal of Biological Chemistry. 2010;285(47):36401-9. Epub 2010/09/21.

25. Cowell IG, Hurst HC. Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain. Nucleic acids research. 1994;22(1):59-65. Epub 1994/01/11.

26. Cowell IG, Skinner A, Hurst HC. Transcriptional repression by a novel member of the bZIP family of transcription factors. Molecular and Cellular Biology. 1992;12(7):3070-7. Epub 1992/07/01.

27. Zhang W, Zhang J, Kornuc M, Kwan K, Frank R, Nimer SD. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. Molecular and Cellular Biology. 1995;15(11):6055-63. Epub 1995/11/01.

28. Motomura Y, Kitamura H, Hijikata A, Matsunaga Y, Matsumoto K, Inoue H, et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat Immunol. 2011;12(5): 450-9. Epub 2011/04/05.

29. Acharya A, Rishi V, Moll J, Vinson C. Experimental identification of homodimerizing B-ZIP families in Homo sapiens. Journal of Structural Biology. 2006;155(2):130-9. Epub 2006/05/27.

30. Cowell IG, Hurst HC. Protein-protein interaction between the transcriptional repressor E4BP4 and the TBP-binding protein Dr1. Nucleic Acids Rresearch. 1996;24(18):3607-13. Epub 1996/09/15.

31. Tong X, Zhang D, Buelow K, Guha A, Arthurs B, Brady HJ, et al. Recruitment of histone methyltransferase G9a mediates transcriptional repression of Fgf21 gene by E4BP4 protein. The Journal of Biological Chemistry. 2013;288(8):5417-25. Epub 2013/01/04.

32. Doi M, Okano T, Yujnovsky I, Sassone-Corsi P, Fukada Y. Negative control of circadian clock regulator E4BP4 by casein kinase Iepsilon-mediated phosphorylation. Current biology. 2004;14(11):975-80. Epub 2004/06/09.

33. Nakabayashi H, Ohta Y, Yamamoto M, Susuki Y, Taguchi A, Tanabe K, et al. Clock-controlled output gene Dbp is a regulator of Arnt/Hif-1beta gene expression in pancreatic islet beta-cells. Biochemical and Biophysical Research Communications. 2013;434(2):370-5. Epub 2013/04/10.

34. Molusky MM, Ma D, Buelow K, Yin L, Lin JD. Peroxisomal localization and circadian regulation of ubiquitin-specific protease 2. PloS One. 2012; 7(11):e47970. Epub 2012/11/08.

35. Silvestris F, Cafforio P, De Matteo M, Calvani N, Frassanito MA, Dammacco F. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. Clinical Cancer Research 2008;14(19):6081-91. Epub 2008/10/03.

36. Pellicelli M, Taheri M, St-Louis M, Beriault V, Desgroseillers L, Boileau G, et al. PTHrP(1-34)-mediated repression of the PHEX gene in osteoblastic cells involves the transcriptional repressor E4BP4. Journal of Cellular Physiology. 2012;227(6):2378-87. Epub 2011/08/10.

37. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, et al. System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nature Genetics. 2005;37(2):187-92. Epub 2005/01/25.

38. Yamajuku D, Shibata Y, Kitazawa M, Katakura T, Urata H, Kojima T, et al. Cellular DBP and E4BP4 proteins are critical for determining the period length of the circadian oscillator. FEBS Letters. 2011;585(14):2217-22. Epub 2011/06/04.

39. Kotaka M, Onishi Y, Ohno T, Akaike T, Ishida N. Identification of negative transcriptional factor E4BP4-binding site in the mouse circadian-regulated gene Mdr2. Neuroscience Research. 2008;60(3): 307-13. Epub 2008/02/05.

40. Bellet MM, Sassone-Corsi P. Mammalian circadian clock and metabolism - the epigenetic link. Journal of Cell Science. 2010;123(Pt 22):3837-48. Epub 2010/11/05.

41. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418(6901):935-41. Epub 2002/08/29.

42. Yan J, Wang H, Liu Y, Shao C. Analysis of gene regulatory networks in the mammalian circadian rhythm. PLoS Computational Biology. 2008; 4(10): e1000193. Epub 2008/10/11.

43. Sancar G, Brunner M. Circadian clocks and energy metabolism. Cellular and molecular life sciences : CMLS. 2014. Epub 2014/02/12.

44. Peek CB, Affinati AH, Ramsey KM, Kuo HY, Yu W, Sena LA, et al. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science. 2013; 342(6158): 1243417. Epub 2013/09/21.

45. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nature Medicine. 2013;19(9):1147-52. Epub 2013/08/13.

46. Husse J, Hintze SC, Eichele G, Lehnert H, Oster H. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption. PloS One. 2012;7(12): e52983. Epub 2013/01/04.

47. Coomans CP, van den Berg SA, Lucassen EA, Houben T, Pronk AC, van der Spek RD, et al. The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity. Diabetes. 2013;62(4):1102-8. Epub 2013/01/01.

48. Kitazawa M. Circadian rhythms, metabolism, and insulin sensitivity: transcriptional networks in animal models. Current Diabetes Reports. 2013; 13(2): 223-8. Epub 2012/12/26.

49. Levi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harbor Symposia on Quantitative Biology. 2007; 72: 465-75. Epub 2008/04/19.

50. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302(5643):255-9. Epub 2003/08/23.

51. Yu X, Rollins D, Ruhn KA, Stubblefield JJ, Green CB, Kashiwada M, et al. TH17 cell differentiation is regulated by the circadian clock. Science. 2013;342(6159):727-30. Epub 2013/11/10.

52. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual Review of Immunology. 2009;27:485-517. Epub 2009/01/10.

53. Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunology. 2008;1(5):339-49. Epub 2008/12/17.

54. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, et al. A validated regulatory network for Th17 cell specification. Cell. 2012;151(2):289-303. Epub 2012/10/02.

55. Reznick J, Preston E, Wilks DL, Beale SM, Turner N, Cooney GJ. Altered feeding differentially regulates circadian rhythms and energy metabolism in liver and muscle of rats. Biochimica et Biophysica Acta. 2013;1832(1):228-38. Epub 2012/09/07.

56. Wu X, Xie H, Yu G, Hebert T, Goh BC, Smith SR, et al. Expression profile of mRNAs encoding core circadian regulatory proteins in human subcutaneous adipose tissue: correlation with age and body mass index. International Journal of Obesity. 2009; 33(9): 971-7. Epub 2009/07/15.

57. Doi M, Nakajima Y, Okano T, Fukada Y. Light-induced phase-delay of the chicken pineal circadian clock is associated with the induction of cE4bp4, a potential transcriptional repressor of cPer2 gene. Proc Natl Acad Sci U S A. 2001;98(14):8089-94. Epub 2001/06/28.

58. Hatori M, Hirota T, Iitsuka M, Kurabayashi N, Haraguchi S, Kokame K, et al. Light-dependent and circadian clock-regulated activation of sterol regulatory element-binding protein, X-box-binding protein 1, and heat shock factor pathways. Proc Natl Acad Sci U S A. 2011; 108(12): 4864-9. Epub 2011/03/09.

59. Male V, Nisoli I, Gascoyne DM, Brady HJ. E4BP4: an unexpected player in the immune response. Trends in Immunology. 2012;33(2):98-102. Epub 2011/11/15.

60. Seillet C, Huntington ND, Gangatirkar P, Axelsson E, Minnich M, Brady HJ, et al. Differential requirement for Nfil3 during NK cell development. Journal of Immunology. 2014;192(6):2667-76. Epub 2014/02/18.

61. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A. 2012;109(4):1210-5. Epub 2011/2/15.

62. Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E, et al. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A.. 2011;108(6):2402-7. Epub 2011/01/21.

63. Blom L, Poulsen LK. IL-1 family members IL-18 and IL-33 upregulate the inflammatory potential of differentiated human Th1 and Th2 cultures. Journal of Immunology. 2012; 189(9): 4331-7. Epub 2012/10/03.

64. Zhao M, Liu Q, Liang G, Wang L, Luo S, Tang Q, et al. E4BP4 overexpression: a protective mechanism in CD4+ T cells from SLE patients. Journal of Autoimmunity. 2013;41: 152-60. Epub 2013/01/24.

65. Weng YJ, Hsieh DJ, Kuo WW, Lai TY, Hsu HH, Tsai CH, et al. E4BP4 is a cardiac survival factor and essential for embryonic heart development. Molecular and Cellular Biochemistry. 2010; 340(1-2):187-94. Epub 2010/02/27.

66. Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, Garvey ME, Frangogiannis NG, Michael LH, et al. Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. Circulation Research. 2010;106(3):546-50. Epub 2009/12/17.

67. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 1993;262(5134):695-700. Epub 1993/10/29.

68. Junghans D, Chauvet S, Buhler E, Dudley K, Sykes T, Henderson CE. The CES-2-related transcription factor E4BP4 is an intrinsic regulator of motoneuron growth and survival. Development. 2004;131(18):4425-34. Epub 2004/08/13.

69. Yu YL, Chiang YJ, Yen JJ. GATA factors are essential for transcription of the survival gene E4bp4 and the viability response of interleukin-3 in Ba/F3 hematopoietic cells. The Journal of Biological Chemistry. 2002;277(30):27144-53. Epub 2002/05/23.

70. Yu YL, Chiang YJ, Chen YC, Papetti M, Juo CG, Skoultchi AI, et al. MAPK-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. The Journal of Biological Chemistry. 2005;280(33):29533-42.

71. Altura RA, Inukai T, Ashmun RA, Zambetti GP, Roussel MF, Look AT. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells. Blood. 1998;92(4):1397-405. Epub 1998/08/08.

72. Beach JA, Nary LJ, Hirakawa Y, Holland E, Hovanessian R, Medh RD. E4BP4 facilitates glucocorticoid-evoked apoptosis of human leukemic CEM cells via upregulation of Bim. Journal of Molecular Signaling. 2011; 6(1): 13. Epub 2011/10/07.

73. Priceman SJ, Kirzner JD, Nary LJ, Morris D, Shankar DB, Sakamoto KM, et al. Calcium-dependent upregulation of E4BP4 expression correlates with glucocorticoid-evoked apoptosis of human leukemic CEM cells. Biochemical and Biophysical Research Communications. 2006; 344(2): 491-9. Epub 2006/04/25.

74. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666-74. Epub 2013/03/06.

75. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-74. Epub 2007/07/03.

76. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146(5):697-708. Epub 2011/09/03.

77. Benito A, Gutierrez O, Pipaon C, Real PJ, Gachon F, Ritchie AE, et al. A novel role for proline- and acid-rich basic region leucine zipper (PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic gene. The Journal of Biological Chemistry. 2006;281(50):38351-7.

78. Bo H, Ghazizadeh M, Shimizu H, Kurihara Y, Egawa S, Moriyama Y, et al. Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2004;71(3):172-80. Epub 2004/07/01.

 

GO BACK to the 2014, April-June issue 
GO BACK to DISCOVERIES 
MEET OUR EDITORIAL BOARD 
SUBMIT A MANUSCRIPT

Email Email us at info@discoveriesjournals.org if you have any questions.

News & Events Latest news from Discoveries

  • 2022, April| AWARDS!

    2022 Discoveries Award winning articles!

    - Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126. 
    27 citations in the past 1 year - $1000 prize

    - Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108. 
    23 citations in the past 2 years - $400 prize

    Congratulations! Prizes will be received by the awardees in July 2022!

  • 2021, July| 2021, Jul-September

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| AWARDS!

    2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.